0.22%
-0.31%
-12.83%
-5.96%
6.51%
28.31%
114.78%
AI Spotlight on ABBV
Company Description
AbbVie Inc.discovers, develops, manufactures, and sells pharmaceuticals in the worldwide.The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products.AbbVie Inc.
has a research collaboration with Dragonfly Therapeutics, Inc.The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Market Data
| Last Price | 175.65 |
| Change Percentage | 0.22% |
| Open | 176.01 |
| Previous Close | 175.26 |
| Market Cap ( Millions) | 310398 |
| Volume | 4037056 |
| Year High | 207.32 |
| Year Low | 153.58 |
| M A 50 | 175.25 |
| M A 200 | 178.73 |
Financial Ratios
| FCF Yield | 5.03% |
| Dividend Yield | 3.58% |
| ROE | 65.72% |
| Debt / Equity | 1178.37% |
| Net Debt / EBIDTA | 263.25% |
| Price To Book | 51.51 |
| Price Earnings Ratio | 60.66 |
| Price To FCF | 19.87 |
| Price To sales | 5.59 |
| EV / EBITDA | 15.44 |
News
- Jan -28 - AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
- Jan -28 - I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
- Jan -27 - Why AbbVie Stock Popped While the Market Flopped on Monday
- Jan -27 - AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
- Jan -27 - AbbVie A Top Socially Responsible Dividend Stock With 3.9% Yield
- Jan -26 - 3 More Cyclical Stocks to Buy for 2025
- Jan -26 - AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
- Jan -25 - 5 Best CEFs This Month For Nearly 10% Yield (January 2025)
- Jan -24 - AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
- Jan -24 - My Near-Perfect Retirement Dividend Portfolio
- Jan -24 - Is AbbVie Stock a Buy?
- Jan -24 - What Can The Dividend Kings Deliver In 2025?
- Jan -23 - AbbVie Completes Acquisition of Nimble Therapeutics
- Jan -23 - AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
- Jan -21 - Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
- Jan -21 - Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
- Jan -21 - 3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
- Jan -19 - Top 4 Immunology Stocks Poised For Growth In 2025
- Jan -17 - Income & Growth: 3 Of The Best Dividend Stocks For Any Market
- Jan -16 - Why the Market Dipped But AbbVie (ABBV) Gained Today
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Immunology
Expected Growth : 4.5 %
What the company do ?
Immunology from AbbVie Inc. focuses on developing treatments for autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease, to improve patient outcomes.
Why we expect these perspectives ?
AbbVie's Immunology segment growth is driven by strong demand for Humira, a leading treatment for autoimmune diseases, and the increasing adoption of Skyrizi and Rinvoq, novel therapies for psoriasis and rheumatoid arthritis. Additionally, the company's robust pipeline and strategic partnerships are expected to fuel future growth, contributing to a 4.5% growth rate.
Segment n°2 -> Neuroscience
Expected Growth : 4.2 %
What the company do ?
AbbVie's Neuroscience segment focuses on developing treatments for neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
Why we expect these perspectives ?
AbbVie's Neuroscience segment growth of 4.2% is driven by strong demand for Botox, a leading neurotoxin brand, and increasing adoption of Vraylar, a treatment for schizophrenia and bipolar disorder. Additionally, the company's strategic investments in research and development, as well as its expanding pipeline of neurodegenerative disease treatments, contribute to the segment's growth.
Segment n°3 -> Other
Expected Growth : 3.8 %
What the company do ?
Other from AbbVie Inc. refers to the revenue generated from miscellaneous sources, including contract manufacturing and royalties, not classified under pharmaceutical or established pharmaceutical products.
Why we expect these perspectives ?
AbbVie's 3.8% growth in 'Other' segment is driven by increasing demand for its aesthetics portfolio, particularly Botox, and strong sales of its eye care products. Additionally, the company's expanding presence in emerging markets and strategic partnerships have contributed to this growth.
Segment n°4 -> Oncology
Expected Growth : 4.8 %
What the company do ?
Oncology from AbbVie Inc. develops and commercializes cancer therapies, including Imbruvica and Venclexta, to improve treatment outcomes for patients with various types of cancer.
Why we expect these perspectives ?
AbbVie's Oncology segment growth of 4.8% is driven by increasing demand for Imbruvica, a leading treatment for blood cancers, and Venclexta, a novel therapy for acute myeloid leukemia. Additionally, the company's strong pipeline, including promising assets such as Veliparib, and strategic collaborations are expected to contribute to future growth.
Segment n°5 -> Aesthetics
Expected Growth : 4.0 %
What the company do ?
Aesthetics from AbbVie Inc. refers to the company's focus on developing and providing innovative, patient-centric solutions for dermatological and aesthetic conditions, enhancing overall skin health and beauty.
Why we expect these perspectives ?
Aesthetics segment growth of 4.0% driven by increasing demand for Botox and Juvederm, expanding into new markets, and growing adoption in emerging markets. Additionally, AbbVie's strategic investments in digital marketing and partnerships with influencers and dermatologists contribute to the segment's growth.
Segment n°6 -> Eye Care
Expected Growth : 3.5 %
What the company do ?
Eye Care from AbbVie Inc. provides prescription ophthalmic products, including treatments for glaucoma, age-related macular degeneration, and dry eye disease.
Why we expect these perspectives ?
AbbVie's Eye Care segment growth of 3.5% is driven by increasing demand for presbyopia treatment with Allergan's Acuvue Oasys, expansion in emerging markets, and growing adoption of cataract surgery with Implantable Lenses. Additionally, the company's strategic partnerships and investments in digital eye care platforms contribute to the segment's growth.
Abbvie Inc. Products
| Product Range | What is it ? |
|---|---|
| Humira | Humira is a prescription medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. |
| Imbruvica | Imbruvica is a prescription medication used to treat certain types of blood cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. |
| Venclexta | Venclexta is a prescription medication used to treat chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). |
| Mavyret | Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection. |
| Rinvoq | Rinvoq is a prescription medication used to treat moderate to severe rheumatoid arthritis. |
| Skyrizi | Skyrizi is a prescription medication used to treat moderate to severe plaque psoriasis. |
| Ubrelvy | Ubrelvy is a prescription medication used to treat acute migraine attacks. |
AbbVie Inc.'s Porter Forces
Threat Of Substitutes
AbbVie Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for various diseases. However, the company's strong brand recognition and patented products mitigate this threat to some extent.
Bargaining Power Of Customers
AbbVie Inc. has a low bargaining power of customers due to the lack of concentration in the buyer's market. The company's products are often prescribed by doctors, reducing the bargaining power of individual customers.
Bargaining Power Of Suppliers
AbbVie Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers for raw materials and services. However, the company's large scale of operations and long-term contracts with suppliers mitigate this threat to some extent.
Threat Of New Entrants
AbbVie Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including significant R&D investments and regulatory hurdles.
Intensity Of Rivalry
AbbVie Inc. operates in a highly competitive pharmaceutical industry, with many established players and new entrants vying for market share. The company faces intense competition in various therapeutic areas, including immunology, oncology, and virology.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 85.15% |
| Debt Cost | 3.95% |
| Equity Weight | 14.85% |
| Equity Cost | 7.07% |
| WACC | 4.41% |
| Leverage | 573.21% |
AbbVie Inc. : Quality Control
AbbVie Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| MRK | Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas … |
| GILD | Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, … |
| BMY | Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, … |
| AMGN | Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Bristol-Myers Squibb
A-Score
1-Year Total Return ->
🥈
AbbVie
A-Score
1-Year Total Return ->
🥉
Gilead Sciences
A-Score
1-Year Total Return ->
4
Merck
A-Score
1-Year Total Return ->
5
J&J
A-Score
1-Year Total Return ->
6
